PATENT CLAIM ANALYSIS

Application Number: 16014975
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-11
Patent Classification: ["514", "789000"]

Abstract:
The present invention discloses a new biomarker miR-134, miR-223, or IL-18, which is positively correlated with AOSD and activities thereof. By detecting the expression level of at least one biomarker in a sample, an effect of detecting the risk and prognosis of a sample provider suffering from a disease is achieved.

Claim (Index 1):
A method for treating adult-onset Still's disease (AOSD), which comprises: administering a pharmaceutical composition to an individual suffering from AOSD to improve or reduce AOSD and symptoms thereof, wherein the pharmaceutical composition comprises an effective amount of a miR-134 inhibitor, a miR-223 inhibitor or a TLR3 receptor inhibitor.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.35714
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14438715', '14989243', '13269404', '13005899', '14380672']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7115423233494123
- 35 USC 102 Novelty (BERT): 0.5320527299279052
- Combined Prediction Score: 0.6935933640072616
- Mean Citation Score: 232.09911
- Max Citation Score: 251.56865
- Similarity Product: 123.38750356912314

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test